pergolide has been researched along with Disease Models, Animal in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Hirai, K; Ono, S; Tokuda, E | 1 |
| Elangbam, CS | 1 |
| Ciobica, A; Hritcu, L; Olteanu, Z; Padurariu, M | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Betz, A; Carlson, BB; Correa, M; Lentini, E; Rios, C; Salamone, JD; Wisniecki, A | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Davidson, C; Ellinwood, EH; Lazarus, C; Lee, TH; Wetsel, WC; Zhang, X | 1 |
| Bossuyt, A; Caveliers, V; Cosyns, B; Droogmans, S; Franken, PR; Garbar, C; Lahoutte, T; Pipeleers-Marichal, M; Schoors, D; Van Camp, G; Weytjens, C | 1 |
| Pei, DS; Sun, YF; Xu, T; Zeng, YM; Zong, XM | 1 |
| Funakoshi, T; Iwata, S; Wakamatsu, M; Yoshimoto, M | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Laute, MA | 1 |
| Hillman, R; Parvez, F; Pendleton, RG; Sayed, M | 1 |
1 review(s) available for pergolide and Disease Models, Animal
| Article | Year |
|---|---|
Drug-induced valvulopathy: an update.
Topics: Animals; Antiparkinson Agents; Appetite Depressants; Cell Proliferation; Disease Models, Animal; Drug Evaluation, Preclinical; Fenfluramine; Heart Valves; Humans; Myofibroblasts; Pergolide; Receptor, Serotonin, 5-HT2B | 2010 |
13 other study(ies) available for pergolide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Disease Models, Animal; Dopamine Agonists; Gene Expression; Lipid Peroxidation; Malondialdehyde; Metallothionein; Mice; Mice, Inbred C57BL; Parkinson Disease; Pergolide; RNA, Messenger | 2009 |
The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Glutathione Peroxidase; Linear Models; Lipid Peroxidation; Male; Malondialdehyde; Maze Learning; Memory; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Wistar; Superoxide Dismutase; Temporal Lobe | 2012 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
Topics: Analysis of Variance; Animals; Cholinergic Agents; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Indoles; Jaw; Male; Movement; Movement Disorders; Parkinsonian Disorders; Pergolide; Phenanthridines; Rats; Rats, Sprague-Dawley; Tacrine | 2005 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.
Topics: Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Glutamic Acid; Male; Neurons; Nucleus Accumbens; Ondansetron; Pergolide; Phosphorylation; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Serotonin Antagonists; Synaptic Transmission | 2007 |
In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Echocardiography; Heart Valve Diseases; Male; Pergolide; Rats; Rats, Wistar | 2007 |
Pergolide protects CA1 neurons from apoptosis in a gerbil model of global cerebral ischemia.
Topics: Analysis of Variance; Animals; Apoptosis; Behavior, Animal; Brain Ischemia; Disease Models, Animal; Dopamine Agonists; Exploratory Behavior; Gerbillinae; Hippocampus; In Situ Nick-End Labeling; Male; Neurons; Pergolide; Proto-Oncogene Proteins c-jun; Time Factors | 2008 |
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Exploratory Behavior; Humans; Levodopa; Male; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Peptide Fragments; Pergolide; Receptors, Dopamine D2 | 2008 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Synergism; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Motor Activity; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Pergolide; Rats; Rats, Wistar | 1999 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Bromocriptine; Disease Models, Animal; Drosophila melanogaster; Genotype; Levodopa; Motor Activity; Nerve Tissue Proteins; Neurons; Parkinson Disease; Pergolide; Postural Balance; Synapses; Synucleins | 2002 |